Tau Rather than TDP-43 Proteins are Potential Cerebrospinal Fluid Biomarkers for Frontotemporal Lobar Degeneration Subtypes: A Pilot Study

H. Bea Kuiperij, Alexandra A M Versleijen, Marijke Beenes, Nicolaas A. Verwey, Luisa Benussi, Anna Paterlini, Giuliano Binetti, Charlotte E. Teunissen, Joost Raaphorst, Helenius J. Schelhaas, Benno Küsters, Yolande A L Pijnenburg, Roberta Ghidoni, Marcel M. Verbeek

Research output: Contribution to journalArticle

Abstract

Background: Frontotemporal dementia (FTD) is a heterogeneous disease both at the clinical, genetic, and pathobiological level. The underlying pathological spectrum (termed FTLD, frontotemporal lobar degeneration) is in most cases defined by accumulation of either tau (FTLD-tau) or TDP-43 proteins (FTLD-TDP). Biomarkers to differentiate these subtypes are not yet available, whereas these are essential requirements to study the natural course of disease and for homogeneous inclusion of patients in clinical studies. Objective: To study if a combination of total (t-) and phosphorylated (p-)tau, and t-TDP-43 and p-TDP-43 proteins in cerebrospinal fluid (CSF) is suitable to discriminate FTLD-tau and FTLD-TDP subtypes. Methods: We developed immunoassays for the quantification of t-TDP-43 and p-TDP-43 proteins and used commercially available assays for the quantification of t-tau and p-tau proteins. We quantified these proteins in ventricular CSF samples from neuropathologically defined FTLD-tau and FTLD-TDP cases to study the reflection of underlying brain pathology in CSF composition, and in lumbar CSF samples from FTLD-tau and FTLD-TDP patients to study the diagnostic potential of CSF biomarkers. Results: In ventricular CSF, t-TDP-43 and t-tau levels, when combined into one model, were significantly different between neuropathologically-defined FTLD-tau and FTLD-TDP cases. In a pilot study using lumbar CSF, the p-tau/t-tau ratio, but not t-TDP-43 levels, were significantly different between FTLD-TDP and FTLD-tau patients. Conclusion: We conclude that with current available methods, CSF tau, rather than TDP-43 proteins, may have diagnostic value in the differentiation of FTLD patients with either tau or TDP-43 pathology.

Original languageEnglish
JournalJournal of Alzheimer's Disease
DOIs
Publication statusE-pub ahead of print - Nov 19 2016

Keywords

  • Biomarkers
  • cerebrospinal fluid
  • frontotemporal lobar degeneration
  • TAR DNA-binding protein 43
  • tau proteins

ASJC Scopus subject areas

  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Tau Rather than TDP-43 Proteins are Potential Cerebrospinal Fluid Biomarkers for Frontotemporal Lobar Degeneration Subtypes: A Pilot Study'. Together they form a unique fingerprint.

  • Cite this

    Kuiperij, H. B., Versleijen, A. A. M., Beenes, M., Verwey, N. A., Benussi, L., Paterlini, A., Binetti, G., Teunissen, C. E., Raaphorst, J., Schelhaas, H. J., Küsters, B., Pijnenburg, Y. A. L., Ghidoni, R., & Verbeek, M. M. (2016). Tau Rather than TDP-43 Proteins are Potential Cerebrospinal Fluid Biomarkers for Frontotemporal Lobar Degeneration Subtypes: A Pilot Study. Journal of Alzheimer's Disease. https://doi.org/10.3233/JAD-160386